I’m not aware of any publicly‑disclosed, exact figure for the capital outlay that Pfizer (or any other company) spent to build a dedicated Mirabegron manufacturing site. Pharmaceutical manufacturing plants are highly variable in size, technology, and regulatory burden, so the cost can span a wide range. Below is a general sense of what goes into building a modern API (active pharmaceutical ingredient) or finished‑product manufacturing facility and the typical cost ranges you might see in the industry.
1. Typical Cost Drivers
| Driver |
What it Covers |
Why It Matters |
| Site & land acquisition |
Purchase or lease of the land, zoning approvals |
Often a significant upfront cost, especially in prime locations. |
| Construction & civil works |
Building envelope, utilities, HVAC, clean‑room infrastructure |
Clean‑room design is expensive; higher‑grade rooms (e.g., ISO Class 5/6) cost more. |
| Process equipment |
Reactors, mixers, crystallizers, filtration, drying, storage, GMP‑compliant handling |
Equipment cost scales with production capacity and process complexity. |
| Quality & control instrumentation |
Analytical instruments, lab facilities, in‑line monitoring |
Critical for ensuring product quality; can be a major expense. |
| Regulatory & compliance |
Documentation, validation, GMP certification, environmental permits |
Validation cycles can add 1‑2 years and cost millions. |
| Capital overhead |
Project management, contingency, financing interest |
Usually 10‑20 % of the total budget. |
2. Rough Cost Ranges by Plant Scale
| Plant Type |
Typical Capacity |
Approximate Capital Cost* |
| Small‑scale API (5–10 k tpa) |
5–10,000 tonnes per annum |
$30 – $70 M |
| Medium‑scale API (20–50 k tpa) |
20,000–50,000 tpa |
$70 – $150 M |
| Large‑scale API (100–300 k tpa) |
100,000–300,000 tpa |
$150 – $400 M |
| Finished‑product plant |
Depends on dosage form (tablets, injectables) |
$200 – $600 M+ |
| Global‑scale, high‑grade (ISO 5/6) plant |
> 1 million tpa |
$600 – $1 billion+ |
These are ball‑park figures based on industry reports, construction cost studies, and publicly disclosed budgets for comparable facilities. Actual costs can be higher or lower depending on geography, technology, and local labor/energy costs.
3. What Makes Mirabegron (Myrbetriq) Unique?
- Chemical Complexity: Mirabegron is a β3‑adrenergic receptor agonist with a relatively complex synthesis route that requires multiple steps and strict purification to meet API purity standards.
- Regulatory Requirements: Because it’s a drug for over‑the‑counter use in many markets (e.g., the U.S. and EU), the manufacturing plant must be GMP‑certified for both the API and the finished product.
- Capacity Needs: Pfizer has marketed Mirabegron worldwide, so the production capacity required is substantial—likely in the 20–50 k tpa range for the API, with a separate finished‑product site that can produce hundreds of millions of tablets annually.
Given those factors, a rough estimate for a dedicated Mirabegron plant would probably fall in the $100 – $300 M range, depending on whether you’re looking at an API plant alone or an integrated finished‑product facility.
4. Bottom‑Line Takeaway
- No single, definitive number exists for the cost of a Mirabegron plant; the cost depends heavily on scale, technology, location, and regulatory scope.
- Industry benchmarks place the capital cost for a medium‑scale API plant in the $70 – $150 M range, while a finished‑product plant can push that to $200 – $600 M or more.
- For a specific drug like Mirabegron, you’d expect a cost on the lower‑ to middle‑end of these ranges if the plant is optimized for commercial production.
Disclaimer
The figures above are estimates drawn from publicly available industry data and generic cost studies. They are not proprietary or insider information, nor are they based on any confidential source. If you need a precise cost figure for a particular project, you would normally engage a specialized engineering or consulting firm that can conduct a detailed feasibility and cost study for your specific site and regulatory requirements.